HC
IOVA icon

Henshaw Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Henshaw Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-41,780
Closed -$139K – 299
2025
Q1 		$139K Buy
41,780
+11,672
+39% +$60.2K 0.01% 290
2024
Q4 		$223K Buy
30,108
+7,965
+36% +$73.8K 0.01% 293
2024
Q3 		$208K Buy
+22,143
New +$210K 0.01% 300

Other funds holding IOVA

MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Henshaw Capital's IOVA Position: Q2 2025 in Review

Henshaw Capital sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 41,780 shares — an estimated $139K sold.

Henshaw Capital first reported a position in IOVA in Q3 2024 and held it in 3 quarters. The position peaked at $223K in Q4 2024. 254 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • Henshaw Capital reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Henshaw Capital sold 41,780 Iovance Biotherapeutics shares in Q2 2025, an estimated $139K.
  • Henshaw Capital first reported a position in Iovance Biotherapeutics in Q3 2024 and held it in 3 quarters.
  • Henshaw Capital's Iovance Biotherapeutics position peaked at $223K in Q4 2024.
  • 254 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on Henshaw Capital's 13F filing for Q2 2025, filed 28 May 2026.